普罗布考联合依达拉奉右莰醇对缺血性脑卒中患者血流动力学及神经功能的影响  

Effect of probucol combined with edaravone on hemodynamics and neurological function in patients with cerebral ischemic stroke

作　　者：梁转栓 刘相勇[2] 王丹[3] LIANG Zhuanshuan;LIU Xiangyong;WANG Dan(Department of Internal Medicine,Xinan County Hospital of Traditional Chinese Medicine,Luoyang Henan 471800;Department of Cardiovascular Medicine,Luoyang Henan 471000,China;Department of Cardiology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang Henan 471000,China)

机构地区：[1]新安县中医院内科,河南洛阳471800 [2]河南科技大学第一附属医院心血管科,河南洛阳471000 [3]河南科技大学第一附属医院心内科,河南洛阳471000

出　　处：《实用心电学杂志》2024年第3期264-268,273,共6页Journal of Practical Electrocardiology

基　　金：河南省医学科技攻关联合共建项目(LHGJ20201355)。

摘　　要：目的探究普罗布考联合依达拉奉右莰醇对缺血性脑卒中(cerebral ischemic stroke,CIS)患者的疗效,及其对脑血流动力学和神经功能的影响。方法回顾性选取82例CIS患者为研究对象,依据不同治疗方案将其分为对照组、观察组,各41例。对照组给予依达拉奉右莰醇,观察组给予依达拉奉右莰醇+普罗布考,均连续治疗14 d。比较两组的临床疗效,美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分,改良Barthel评分(modified Barthel index,mBI),简易精神状态检查表(mini-mental state examination,MMSE)评分,大脑中动脉平均流速、峰流速对称性差值(difference in symmetry of peak flow velocity,DVp)、平均流速对称性差值(difference in symmetry of average flow velocity,DVm)、峰流速,血清闭合蛋白、高敏C反应蛋白(hs-CRP)、基质金属蛋白酶(matrix metalloproteinase,MMP)-9、网膜素-1及不良反应的发生情况。结果治疗后观察组总有效率高于对照组(92.68%vs.75.61%,P<0.05)。治疗后观察组mBI、MMSE评分高于对照组,NIHSS评分低于对照组(P<0.01),而大脑中动脉平均流速、峰流速及网膜素-1水平均高于对照组,DVp、DVm及血清闭合蛋白、hs-CRP、MMP-9水平均低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论普罗布考联合依达拉奉右莰醇对CIS疗效确切,可改善患者脑血流动力学,抑制炎症反应,减轻神经功能障碍,且安全性较高。Objective To explore the efficacy of probucol combined with edaravone in patients with cerebral ischemic stroke(CIS),and the influence on their hemodynamics and neurological function.Methods We retrospectively selected 82 CIS patients as research subjects;they were divided into control group and observation group according to different therapeutic regimens,each with 41 cases.The control group was treated with edaravone while the observation group was treated with edaravone plus probucol.Patients of the two groups were continuously treated for 14 days.The clinical efficacy,National Institute of Health stroke scale(NIHSS)score,modified Barthel index(mBI),mini-mental state examination(MMSE)score,the average velocity(Vm),difference in symmetry of peak flow velocity(DVp),difference in symmetry of average flow velocity(DVm)and peak flow rate(Vp)of the middle cerebral artery,serum Occludin,high sensitivity C reactive protein(hs-CRP),matrix metalloproteinase(MMP)-9 and omentin-1,and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group after treatment(92.68%vs.75.61%,P<0.05).The mBI and MMSE scores of the observation group were higher than those of the control group after treatment while NIHSS score was lower(P<0.01);the Vm and Vp of the middle cerebral artery,and omentin-1 level were all higher than those of the control group while DVp,DVm,and serum Occludin,hs-CRP and MMP-9 levels were all lower than those of the control group(P<0.05).The incidence of adverse reactions did not vary significantly between the two groups(P>0.05).Conclusion Probucol combined with edaravone shows definite efficacy on CIS,which improves patientscerebral hemodynamics,inhibits inflammatory reaction,and relieves neural dysfunction with high safety.

关 键 词：普罗布考 依达拉奉右莰醇 缺血性脑卒中 脑血流动力学 

分 类 号：R743.33[医药卫生—神经病学与精神病学]